KRAS Knockout HeLa Cell Lysate

Product Discontinued

KRAS Knockout HeLa Cell Lysate Summary

• Preparation Method: Knockout achieved by using CRISPR/Cas9,1 bp insertion in exon 2
• Gene: KRAS

Applications/Dilutions

• Dilutions:
  • Western Blot
• Application Notes: You will receive 1 vial (100ug) of knockout cell lysate and 1 vial (100ug) of Parental cell lysate. Lysate can be diluted with 1X SDS sample buffer and will be stable at -20 degrees C for 12 months. Minimize freeze-thaw cycles.

Packaging, Storage & Formulations

• Storage: Store at -20C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.
• Buffer: 0.1 mg cell homogenate lyophilized in RIPA buffer made with double-knockout cell lines.
• Concentration: LYOPH
• Reconstitution Instructions: To use as WB negative control, spin down briefly and resuspend in 100 uL 1xSDS sample buffer (2% SDS, 60 mM Tris-HCl pH 6.8, 10% Glycerol, 0.02% Bromophenol blue, 60 mM beta-mercaptoethanol). Boil the lysate for 3 - 5 minutes before loading it onto gel.

Lysate Details for Array

• Type: Knockout HeLa Cell

Notes

Powered by EDIGENE.
Validation of antibody specificity is critical and verification of antibody performance against knockout samples is one way to guarantee that an antibody recognizes a specific target. Novus' KO cell lysate can be used as a negative control for western blots and to confirm the specificity of antibodies.

Alternate Names for KRAS Knockout HeLa Cell Lysate

• cellular c-Ki-ras2 proto-oncogene
• c-Ki-ras
• C-K-RAS
• GTPase KRas
• KI-RAS
• Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homolog
• K-Ras 2
• K-ras p21 protein
• KRAS1
• K-RAS2A
• K-RAS2B
• KRAS2NS3
• K-RAS4A
• K-RAS4B
• NS
• oncogene KRAS2
• PR310 c-K-ras oncogene
• RASK2c-Kirsten-ras protein
• transforming protein p21
• v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
• v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Lysates are guaranteed for 6 months from date of receipt.

Bioinformatics

• Gene Symbol: KRAS